OPEN: 2027 SVRF Independent Investigator Track letter-of-intent submission open through November 10, 2026, 5:00 p.m. PST. Full proposal by invitation only, February 2, 2027 at 5:00 p.m. PST. Reviewed official 2027 Request for Proposals November 1, 2026.
National – Additional Ventures 2027 Single Ventricle Research Fund: Independent Investigator Track (Up to $600,000; November 10 LOI)
FundingUp to $600,000 in direct costs per Independent Investigator Track award over three years; up to 10% additional indirect costs allowed under funder policy. No overall 2027 funding pool published.
Deadline2027 SVRF letter of intent: November 10, 2026, 5:00 p.m. Pacific Standard Time (PST). Invited full proposal: February 2, 2027, 5:00 p.m. PST. Invitations by December 15, 2026.
Last verified2026-11-01
Required next actionReview Additional Ventures 2027 RFA; confirm lead PI doctoral degree and independent investigator status, host institution nonprofit academic/research or eligible biomedical governmental entity, project mechanistic fit and legal eligibility. Submit through ProposalCentral under Independent Investigator Track by November 10, 2026 at 5:00 p.m. PST. LOI: 500-character summary, 2500-character research goals/strategy, 500-character impact statement; one LOI per investigator. If invited December 15, prepare full proposal by February 2, 2027 at 5:00 p.m. PST including institutional officials, biosketches, project plan, detailed USD budget, open-data and ethics compliance.
Broad Eligibility
Independent doctoral-level investigators at qualifying nonprofit academic or research institutions (including universities and medical schools) or certain governmental biomedical research agencies in the U.S. or abroad, subject to U.S. sanctions/legal restrictions. Independent faculty including non-tenure-track instructors and assistant professors eligible; up to five co-investigators may collaborate. Foundational mechanistic research in single ventricle congenital heart disease with clear long-term outcomes relevance; no standalone clinical trials, registry/biorepository builds, primarily prototype or device development.
Atlas Analysis
Source verified November 1, 2026 against the Additional Ventures controlling 11-page 2027 RFA hosted by Tel Aviv University research authority at https://research-authority.tau.ac.il/sites/resauth.tau.ac.il/files/Additional-Ventures-2027-SVRF-RFP.pdf and the official program at https://www.additionalventures.org/funding/single-ventricle-research-fund/. RFA page 3 specifies maximum $600,000 direct costs for Independent Investigator over three years, up to 10% indirect in addition; overall 2027 program pool not published. RFA page 3 and page 6 specify Nov 10, 2026 LOI 5pm PST and invited full proposal Feb 2, 2027 5pm PST. RFA page 5 verifies eligible institutions worldwide subject to legal restrictions, doctoral PI qualification, collaboration up to five co-PIs, excluded registry and clinical trials. ProposalCentral online portal required; one LOI per investigator. Allowable requested expenses include capped salary, research equipment, reagents, tuition, software, travel, publication and subject-related costs; IRB/IACUC before initial payment where applicable. No mandatory cash match published. Institution receives funds, not individual investigator. Genuine financial assistance, not procurement. Internal catalog grant identifier distinguishes this track from career development.
Additional Ventures 2027 Single Ventricle Research Fund: Independent Investigator Track
Additional Ventures has opened the seventh 2027 Single Ventricle Research Fund competition for foundational research into single ventricle heart disease and its long-term organ and multi-organ complications. This is a competitive investigator research grant, not a government equipment or vendor procurement contract.
Applicant funding and deadlines
Up to $600,000 in direct costs over three years is available for an individual Independent Investigator Track award. Indirect costs of up to 10 percent are provided in addition to the direct-cost award. The funder has not published a specific overall 2027 pool or a mandatory applicant matching-fund percentage on the current program page.
Letter of intent deadline: November 10, 2026, 5:00 p.m. Pacific Standard Time (PST). The controlling 2027 Request for Proposals confirms the closing hour. Applicants invited by December 15, 2026 may submit full proposals by February 2, 2027, 5:00 p.m. PST. Anticipated funding begins July 1, 2027.
Eligibility and scientific fit
Principal investigators must hold doctoral degrees such as PhD, MD, or PsyD. Independent investigators, including instructors, assistant professors and tenured or non-tenured researchers, may apply. Collaborative proposals are encouraged; up to five co-investigators may be listed, each meeting the same investigator eligibility conditions. Applicants must be affiliated with a qualifying nonprofit academic or research institution, including eligible universities, medical schools and certain biomedical governmental research agencies in the United States or abroad. International applications are generally welcome, subject to U.S. sanctions and applicable legal restrictions. The 2027 RFA is the controlling eligibility document.
Projects must focus on foundational, hypothesis-driven mechanisms affecting outcomes of single ventricle heart disease, including circulatory regulation, lymphatic and immune disorders, liver and kidney health, heart function, rhythm, and neurodevelopment. Clinical trials, registry or biorepository builds, and predominantly device design, optimization, prototype or precommercial testing are excluded.
How to apply
Use ProposalCentral (www.proposalcentral.com) and select the Single Ventricle Research Fund opportunity and the Independent Investigator Track. Submit the LOI by November 10, 2026 at 5:00 p.m. PST; only one LOI is permitted per investigator, although the investigator may collaborate on other LOIs. LOI fields include applicant institution, principal investigator, project summary (500 characters), scientific goals and strategy (2,500 characters), and impact/fit statement (500 characters). Full proposals are invitation-only, with detailed budget, biosketches, scientific plan, relevant IRB/IACUC materials, and the funder’s reporting/data-sharing conditions. Official 2027 program: https://www.additionalventures.org/funding/single-ventricle-research-fund/ . Controlling 2027 RFA: https://research-authority.tau.ac.il/sites/resauth.tau.ac.il/files/Additional-Ventures-2027-SVRF-RFP.pdf .
From Funding to Implementation · School Health Solution
Turn school-health funding into a clinically capable care model.
Dr. Miltie N9+ can support clinician-directed remote exams in school settings, helping care teams move beyond video-only encounters when a funded program calls for stronger pediatric access.
Source verificationReferenced source · www.additionalventures.orgAtlas last verified this record 2026-11-01. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗
